FAQ

Q：How was the Company established?

A：The Company was established aiming to utilize antibodies against diagnosis and drug discovery targets for healthcare, based on expressing protein and antibody generating technologies developed by LSBM, Research Center for Advanced Science and Technology, the University of Tokyo.
As for details, please refer to “About us”.

Q：What is the corporate policy?

A：Our corporate policy is that we are committed to contributing to global healthcare with our cutting-edge antibody technologies.

Q：What fields of business does the Company develop?

A: We develop business in the three fields; antibody drug discovery, antibody research support service, and antibody/reagent sales.
Please refer to the “Business” for details.

Q：When did the Company go public?

A：June 22, 2021.

Q：What is the origin of the company name?

A：“Perseus” comes from a great hero in a Greek myth. “Proteomics” means the research on structures and functions of protein. Perseus is said to have killed Medusa and to have saved Andromeda from Tiamat, a sea monster, by showing it Medusa’s head. We compare the arms he used for defeating Tiamat including Pegasus and Medusa’s head to our antibody technologies. The Company name represents our mission to save patients (Andromeda) by fighting cancers and other diseases which are difficult to cure (Tiamat).

Q：Where can I find the latest business results?

A：Visit "Financial Results" or "Financial Highlights" on our website. We also provide “Presentation Materials” every six months.

Q：When is your fiscal year-end?

A：Our fiscal year ends on March 31 and the first half ends on September 30. We announce the year-end business results in May, and quarterly results in August, November, and February.

Q：Where are your stocks listed?

A：On the Growth Market of Tokyo Stock Exchange.

Q：What is the securities code number?

A：4882.

Q：What is the stock trading unit of Perseus Proteomics?

A：1 trading unit is 100 shares.

Q：What is your dividend policy?

A：We recognize profit return to shareholders as an important issue in management, however, we have not been able to pay dividend so far. Development of medical drugs requires big upfront investment and long-range period. Therefore, we strive to increase internal reserve and prioritize in securing R&D expenses for a while. When we can distribute dividends, basically we make payments annually after approval at a general shareholders’ meeting. We can also distribute interim dividends by the resolution of a Board of Directors for swift payments as stipulated in the Articles of Incorporation pursuant to the Paragraph 5, Article 454 of the Companies Act.

Q：How can I purchase Perseus Proteomics stocks?

A：Please contact securities company about the detail.

Q：How much is the stock price of Perseus Proteomics?

A：Please click here.

Q：Who is the shareholder registry administrator for Perseus Proteomics?

A：Mitsubishi UFJ Trust Bank.

Q：How can I transfer stock or change the address on my shareholder account?

A：Please contact the securities company where you have an account.

Q：When is a general shareholders meeting held?

A：A general shareholders meeting is held in the end of June every year. We will notice the date, venue and other information in late May or early June on this website.

Q：How do I exercise my voting right at a shareholders’ meeting?

A：We send a convocation notice and a voting form to the shareholders listed in the Shareholders Registry at the end of the record date (March 31). Shareholders can exercise the voting rights by:

• attending the shareholders’ meeting bringing with the execution form.
• electronic voting.
• returning the voting form after indicating your approval or disapproval of each proposal by post.

Q：Which industry sector does the Company belong to?

A：Medical industry.

Q：How can I contact IR group?

A：Select “IR” on “Inquiry” form and send us your inquiry.

In your PV Phase 1 clinical trial, the sample size is only 6.  Do you foresee any problem in the number for proving efficacy?

The primary purpose of a Phase 1 clinical trial is to confirm safety.  The safety of PPMX-T003 has been confirmed in the trial among 40 healthy volunteers at doses up to 0.25mg/kg.  In the PV patients trial, safety of doses of 0.25mg/kg or higher, and treatment efficacy have been assessed as secondary endpoint.
The inclusion criteria specify PV patients with no existing drugs history as the subjects, a population that is relatively small in Japan.  We have decided the number through discussions with PMDA taking the conditions into account.  While a larger number of subjects increases the reliability, it also increases the required time and development costs proportionately.  The number of subjects is decided by the type of the disease, target population, and several other factors including those mentioned above.

Some biotech ventures conduct even a phase 3 clinical trial in house.  Is there any reason why you finish the development of PPMX-T003 for PV treatment at the phase 1 completion?

Conventionally, out-licensing agreements at early stage are often seen, however, it has become more common to conduct up to Phase 1 clinical trials before agreements, and as you mentioned, out-licensing after Phase 2 or Phase 3 trials is also seen.  The stage of clinical trials conducted depends on the strategies and circumstances of each company.  Depending on the target disease, completing a Phase 3 trial in-house and obtaining approval can maximize revenue, however, it also involves significant risks and development costs.  Besides, the necessary number of cases and trial costs vary greatly depending on the disease.  In particular, for Phase 3 trials, the required number of cases vary to demonstrate statistical advantages due to factors including comparison with existing drugs and variability in symptoms.  On the other hand, the required number of cases are fewer as for the diseases without existing drugs or highly fetal diseases.  We have selected out-licensing after a Phase 1 trial as a result of comprehensive consideration.

Will you announce registration of important patents or pipeline-related patents?  If so, after registration or after approval?  

We will basically announce registration of important patents and pipeline-related patents.  The announcement timing is after registration, considering when the patents are granted.

Will you announce important patents registration overseas?

We assess the importance level case by case and file applications in various countries as necessary, however, we only announce registrations in key countries.   

What does data locking mean? How long does it take to complete it?

Data locking refers to the state in which the information recorded in the case report form regarding a patient's treatment history and test results, as specified in the protocol, has been verified by the monitor to ensure that there are no discrepancies with the information in the medical records at the clinical trial site.  All issues or questions arisen from this verification process have been resolved. The duration required for data locking varies depending on the circumstances of the clinical trial site and the doctors, as well as the number of issues or questions identified during the verification process. Therefore, it is not uniform and differs for each case.

Will you announce the completion of data locking and individual data after completion? 

We have not decided yet whether or not to announce the completion of data locking.  Individual data, however, will not be disclosed.  We would like to announce the summary and other information in some method.